trending Market Intelligence /marketintelligence/en/news-insights/trending/qNszSzT6y7VcflslsJbeMw2 content esgSubNav
In This List

60° Pharmaceuticals seeks US FDA approval for preventive malaria medication

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


60° Pharmaceuticals seeks US FDA approval for preventive malaria medication

60° Pharmaceuticals LLC is seeking approval from the U.S. Food and Drug Administration for Tafenoquine for the prevention of malaria in adults.

The company entered into a cooperative research and development agreement with the U.S. Army Medical Materiel Development Activity in 2014 for the development of the drug.

Tafenoquine has been studied in more than 30 clinical trials involving more than 4,000 participants.